Skip to main content

Table 2 Pregnancy outcomes of artemether and lumefantrine use during pregnancy

From: A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy

Publication Drug (n) Trimester Pregnancy outcomes
1 2/3 Prematurity Miscarriage Stillbirth Congenital abnormality Low birth weight Neo-natal death
Wang 1989[20] A 0 2 0/2    0/2a   
Sowunmi et al., 1998[15] A + MQ (22), A (23) 0 45       
McGready et al. , 2001[17] A + MQ/AS/C (10), AL (1)   1/9     
Adam et al., 2004[16] A 1 27 1/28b    0/28   
McGready et al., 2006[21] AL 0 13* 1c    0   
McGready et al. , 2008[22] AL 0 125 3/117 (2.6%) 0/125 1/125 (0.8%) 3/117 (2.6%) 14/99 (14.1%)  
AS 0 128 10/120 (8.3%) 1/128 (0.8%) 1/128 (0.8%) 4/120 (3.3%) 20/101 (19.8%)  
Kaye et al. , 2008[23] AL 0 58       
Adam et al., 2009[24] A (48), AL (3) 51 0   2d   0   
Piola et al. , 2010[25] AL 0 152 12/143 (8.4%) 3/144 (2.1%) 2/144 (1.4%) 3/143 (2.1%) 12/120 (10.2%) 3/144 (2.1%)
Q 0 152 17/137 (12.4%) 4/137 (2.9%) 3/137 (2.2%) 2/137 (1.5%) 16/119 (13.4%) 6/137 (4.4%)
Manyando et al. , 2010[26] ALe 156 348 71/504 (14.1%) 7/504 (1.4%) 9/504 (1.8%) 8/449 (1.8%) (29/449 [6.5%])f 9.0% 11/475 (2.3%)
AL 1st trimester 156   20/150 (13.3%) 7/159 (4.4%)g 2/135 (1.5%) 1/130 (0.8%) (9/130 [6.9%])f   4/135 (3%)
SP/Qe 138 378 90/516 (17.4%) 8/516 (1.6%) 13/516 (2.5%) SP 6/444 (1.4%) (18/444 [4.1%])f 7.7% 11/480 (2.3%)
SP/Q 1st trimester 138   28/135 (20.7%) 0/135 3/129 (2.3%) 3/121 (2.5%) (8/121 [6.6%])f   2/129 (1.6%)
Sangaré et al., 2011[27] AL (260)h 53i 207    7/500j    
  1. A artemether; AL artemether-lumefantrine; AS artesunate; C clindamycin; MQ mefloquine; Q quinine; SP sulphadoxine-pyrimethamine; *These 13 exposures are not included in the total count of exposures to AL in pregnant women as they were also included in McGready et al., 2008 [22]; a5 years; binfant died, 2nd–3rd trimester exposure; cassociated with maternal urinary tract infection; dA group, associated with quinine infusion for further malaria attack; eAL group n = 495, AL exposure 504, SP group n = 506, SP/Q exposure n = 516; fincluding umbilical hernia; g2 multiple malaria episodes, 1 syphilis, 1 concomitant salbutamol and AL for threatened abortion; h260 reports of AL treatment for an episode of malaria; i26 received only AL in the 1st trimester; jtotal study population.
\